top of page
Developing safe, convenient, disease-modifying treatments for food allergies.
Profile
Join date: Jun 4, 2018
Posts (29)
Jun 22, 2025 ∙ 2 min
Aravax Appoints Dr Adrian Parry as Director of CMC as it Continues to Build Phase 3 Development Capabilities
Melbourne, Australia and Oxford, UK– 23 June 2025, a clinical-stage biotechnology company developing next-generation, disease-modifying...
512
0
Jun 1, 2025 ∙ 2 min
Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development
Melbourne, Australia and Oxford, UK– 2 June 2025, Aravax, a clinical-stage biotechnology company developing next-generation,...
389
0
Jan 20, 2025 ∙ 2 min
Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer
Melbourne, Australia and Oxford, UK– 21 January 2025 , Aravax, a clinical-stage biotechnology company developing precisely targeted...
627
0
aravaxweb
Admin
More actions
bottom of page